Published in final edited form as:

Pediatr Neurol. 2016 July ; 60: 83–87. doi:10.1016/j.pediatrneurol.2016.03.011.

PEHO Syndrome May Represent Phenotypic Expansion at the Severe End of the Early-Onset Encephalopathies

Pawel Gawlinski, PhD^a, Renata Posmyk, MD^b, Tomasz Gambin, PhD^{a,c}, Danuta Sielicka, MD^d, Monika Chorazy, MD^e, Beata Nowakowska, PhD^a, Shalini N. Jhangiani, MSc^f, Donna M. Muzny, MSc^f, Monika Bekiesinska-Figatowska, MD, PhD^g, Jerzy Bal, PhD^a, Eric Boerwinkle, PhD^{f,h}, Richard A. Gibbs, PhD^f, James R. Lupski, MD, PhD, DSc (hon)^{f,i,j,k}, and Wojciech Wiszniewski, MD, PhD^{a,i,*}

^aDepartment of Medical Genetics, Institute of Mother and Child, Warsaw, Poland ^bDepartment of Clinical Genetics, Podlaskie Medical Center, Bialystok, Poland ^cInstitute of Computer Science, Warsaw University of Technology, Warsaw, Poland ^dDepartment of Pediatric Ophthalmology, Children's University Hospital, Bialystok, Poland ^eDepartment of Neurology, Medical University Hospital, Bialystok, Poland ^fHuman Genome Sequencing Center, Baylor College of Medicine, Houston, Texas ^gDepartment of Diagnostic Imaging, Institute of Mother and Child, Warsaw, Poland ^hHuman Genetics Center and Institute of Molecular Medicine, University of Texas-Houston Health Science Center, Houston, Texas ⁱDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas ^jDepartment of Pediatrics, Baylor College of Medicine, Houston, Texas ^kTexas Children's Hospital, Houston, Texas

Abstract

BACKGROUND—Progressive encephalopathy with edema, hypsarrhythmia and optic atrophy (PEHO) syndrome is a distinct neurodevelopmental disorder. Patients without optic nerve atrophy and brain imaging abnormalities but fulfilling other PEHO criteria are often described as a PEHO-like syndrome. The molecular bases of both clinically defined conditions remain unknown in spite of the widespread application of genome analyses in both clinic and research.

METHODS—We enrolled two patients with a prior diagnosis of PEHO and two individuals with PEHO-like syndrome. All four individuals subsequently underwent whole-exome sequencing and comprehensive genomic analysis.

RESULTS—We identified disease-causing mutations in known genes associated with neurodevelopmental disorders including *GNAO1* and *CDKL5* in two of four individuals. One patient with PEHO syndrome and a *de novo* *GNAO1* mutation was found to have an additional *de novo* mutation in *HESX1* that is associated with optic atrophy.

*Communications should be addressed to: Dr. Wiszniewski; Department of Molecular and Human Genetics; Baylor College of Medicine; One Baylor Plaza; Houston, TX 77030-3411. www@bcm.edu.

Conflicts of Interest: J.R.L. has stock ownership in 23andMe and Lasergen and is a paid consultant for Regeneron. J.R.L. is a coinventor on multiple U.S. and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from the chromosomal microarray analysis and clinical exome sequencing offered in the Baylor Medical Genetics Laboratories (<http://www.bcm.edu/geneticlabs/>). Other authors have no disclosures relevant to the article.

CONCLUSIONS—We hypothesize that PEHO and PEHO-like syndrome may represent a severe end of the spectrum of the early-onset encephalopathies and, in some instances, its complex phenotype may result from an aggregated effect of mutations at two loci.

Keywords

PEHO; encephalopathy; whole-exome sequencing; optic atrophy; neurodevelopmental disorder

Introduction

Progressive encephalopathy with edema, hypsarrhythmia and optic atrophy (PEHO) syndrome (Mendelian Inheritance in Man [MIM]#260565) is a rare genetic disorder that was originally described in the Finnish population.¹ The cardinal features of PEHO syndrome include (1) infantile hypotonia, (2) seizure disorder, (3) profound delay in motor and intellectual development, (4) progressive brain atrophy, and (5) atrophy of the optic disc by the age of 2 years. The aforementioned criteria are considered necessary for a diagnosis of PEHO syndrome and together with supportive findings that may include subtle dysmorphic features, edema of the face and limbs, evidence of dysmyelination on brain magnetic resonance imaging studies and slowing of nerve conduction velocities have been used to identify patients with this condition.^{2–4} Patients who are lacking neuroradiologic and/or ophthalmologic signs have been referred to as PEHO-like syndrome. Families with multiple affected siblings were reported; therefore, an autosomal recessive mode of inheritance has been proposed; however, most PEHO-spectrum patients represent sporadic patients.^{3,5,6}

Material and Methods

Study subjects

Subjects were selected on the basis of their phenotype and, with their written consent, were studied via protocols approved by the institutional review boards for the protection of human subjects of Baylor College of Medicine.

Genomic DNA preparation

DNA was isolated from clotted whole blood by using the Clotspin Baskets and the Gentra PureGene Blood Kit (Qiagen, Germantown, MD) according to the manufacturer's instructions.

Whole-exome sequencing

After obtaining informed consent, we applied whole-exome sequencing (WES) to the probands at Baylor College of Medicine Human Genome Sequencing Center through the Baylor Hopkins Center for Mendelian Genomics.⁷

Results

We have enrolled two patients with the prior diagnosis of PEHO syndrome (IMD1 and IMD2) and two with PEHO-like syndrome (IMD3 and IMD4).

Patients IMD1 and IMD2 underwent comprehensive evaluation by genetics at 6 years and 4.5 years of life and were found to fulfill clinical criteria required for the diagnosis of PEHO syndrome (Table). Patients were born to nonconsanguineous parents, and their family history was noncontributory. Comparative genomic hybridization (array CGH) studies did not reveal any pathogenic copy number variants. WES studies for the patients and their parents were performed using a trio approach searching for sequence variants in known and candidate genes. In patient IMD1, we identified two *de novo* mutations: chr16: 56226501G>A (c.134G>A, p.Gly45Glu) in *GNAOI* and chr3:57233922G>A (c.25G>A, p.Ala9Thr) in *HESX1* that potentially contributed to the observed phenotype; the mutations were confirmed by Sanger sequencing (Fig 1). Both *GNAOI* and *HESX1* are genes associated with known human disorders. The *GNAOI* mutation has not been identified in available mutation databases including Exome Sequencing Project (ESP), 1000 Genomes, Exome Aggregation Consortium (ExAC), and internal Baylor Hopkins Center for Mendelian Genomics database.^{8–10} The *HESX1* mutation was not recorded in the aforementioned databases except for ExAC where it was found in three of 60,703 individuals, all coming from South Asia (minor allele frequency = 0.00002471). The *GNAOI* p.Gly45Glu mutation was predicted to be pathogenic or likely pathogenic by available bioinformatics tools including Sorting Intolerant From Tolerant, MutationTaster, PolyPhen, whereas *HESX1* p.Ala9Thr variant was called benign by the same algorithms. WES analysis for patient IMD2 failed to identify mutation in either a known or candidate gene that could potentially explain the existing phenotype.

Two patients, IMD3 and IMD4, had clinical findings suggestive of PEHO-like syndrome (Table). Brain-imaging studies for patient IMD3 showed cerebral atrophy but no signs of cerebellar abnormalities (Fig 2) and normal brain imaging studies in IMD4. Both patients were born to non-consanguineous couples with no prior family history of neurodevelopmental problems and thus represented sporadic cases. No disease-associated copy number variant was detected by clinical array CGH.

Patient IMD3 was found to have a *de novo* *CDKL5* mutation, chrX: 18606145C>T (c.626C>T, p.Pro209Leu) that was predicted to be deleterious by bioinformatics tools and was not recorded in mutation databases (Fig 2). *CDKL5* is a known gene associated with early-onset epileptic encephalopathy (EE). WES did not detect a disease mutation for patient IMD4.

Discussion

Comprehensive genomic analysis by WES for two patients with a prior diagnosis of PEHO syndrome and two patients with PEHO-like features identified sequence variants in three known genes in two of four patients. Female patient IMD1 was found to have two *de novo* mutations in *GNAOI* and *HESX1* that could potentially explain her complex clinical presentation. Mutations in *GNAOI* are associated with early-onset EE type 17, EIEE17 (MIM#615473), that exhibit significant clinical overlap with PEHO.¹¹ Mutations in *GNAOI* have never been associated with optic nerve pathology and thus cannot fully explain the PEHO phenotype observed in this patient.

We conducted additional analysis of WES data and identified another *de novo* mutation in *HESX1*.¹² This is a well-known “disease gene” associated with a number of clinical phenotypes including, septo-optic dysplasia, optic nerve abnormalities, and congenital pituitary deficiencies. *De novo* mutations or an autosomal dominant pattern of inheritance with incomplete penetrance has been reported in subjects with combined pituitary hormone deficiency and optic nerve hypoplasia.¹³ We identified a *HESX1* p.A9T mutation which is predicted to be benign by bioinformatic tools. Interestingly, Thomas et al.¹⁴ identified that a *HESX1* p.Q6H mutation that localizes in close proximity to p.A9T was recorded in mutation databases and predicted nonpathogenic but was clearly associated with septo-optic dysplasia and demonstrated incomplete penetrance in an affected family. Cumulatively, these data implicate *HESX1* p.A9T mutation as a potential genetic factor determining ocular pathology in our patient with PEHO syndrome. We hypothesize that the patient’s complex phenotype consisting of encephalopathy and optic atrophy may result from a combined effect of mutations at two Mendelian loci, *GNAO1* and *HESX1*, and thus represents a blended phenotype.^{15,16}

It has been estimated that nearly 5% of patients with molecular diagnosis established by WES have disease mutations in two genetic loci that are associated with the observed phenotype.^{15,16} Co-occurrence of mutations in *GNAO1* and *HESX1* may suggest that some PEHO patients represent a blended phenotype resulting from mutations at two distinct independent Mendelian loci.

We also identified mutations in a known encephalopathy gene in one patient with PEHO-like syndrome. In a male patient IMD3, a *de novo* mutation in *CDKL5* was detected that was predicted to be pathogenic. Mutations in *CDKL5* are found in patients with Rett-like phenotype.^{17,18} Interestingly, affected males present with a more severe spectrum of the disease and their clinical manifestations overlap with PEHO-like syndrome as both groups have intractable seizures, hypsarrhythmia, brain atrophy, and profound mental retardation.¹⁹

Phenotyping patients and establishing diagnosis may be a challenging task because many genetic disorders are clinically and genetically heterogeneous. The phenotyping approach to disease classification is further challenged by recent reports of the prevalence of blended phenotypes and phenotypic expansions, where mutations in one locus are identified in patients demonstrating clinical features beyond the clinical characteristic accepted for a particular clinical entity, among patients with genetic disorders.⁹ PEHO syndrome has been a well-established clinical entity, but the question whether PEHO-specific gene exists requires further investigations. As of today, genes associated with only half of all known Mendelian phenotypes have been discovered leaving a wide field for future discoveries.

In aggregate, we postulate that at least some individuals with PEHO-spectrum disorders may represent phenotypic expansion at the severe end of the early-onset encephalopathies associated with known EE genes. Optic nerve atrophy that distinguishes patients with PEHO from PEHO-like syndrome may result from a genetic mutation and/or possibly represent an end result of generalized neurodegenerative disorder of progressive brain atrophy. PEHO syndrome diagnosed in patient IMD1 in whom mutations in *GNAO1* and *HESX1* were detected may represent an example of a blended phenotype. We consider the coexistence of

two *de novo* mutations in a patient with PEHO an exception rather than a rule, but this observation generates an hypothesis that PEHO syndrome may result in some instances from inherited and/or *de novo* mutation in two or more Mendelian loci; however, a combination of genetic and environmental factors cannot be excluded. We anticipate that there are individuals with PEHO syndrome that represent a truly Mendelian disorder resulting from mutations in a single gene, but mutations in this gene will likely account for a fraction of cases.

Acknowledgments

The authors thank all the family members and collaborators that participated in this study. This work was supported by the US National Human Genome Research Institute (NHGRI) and National Heart, Lung, and Blood Institute (NHLBI) grant U54HG006542 to the Baylor-Hopkins Center for Mendelian Genomics, NINDS grant RO1 NS058529 to J.R.L., Career Development Award K23NS078056 from NINDS, and National Science Center, Poland (DEC-1012/06/M/NZ2/00101) to W.W. Web references: OMIM (Online Mendelian Inheritance in Man): <http://www.ncbi.nlm.nih.gov/omim>; NHLBI GO Exome Sequencing Project (ESP) server: <http://evs.gs.washington.edu/EVS/>; 1000 Genomes: <http://www.1000genomes.org/>; and ExAC: <http://exac.broadinstitute.org/>.

References

- Salonen R, Somer M, Haltia M, Lorentz M, Norio R. Progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO syndrome). *Clin Genet.* 1991; 39:287–293. [PubMed: 2070547]
- Riikonen R. The PEHO syndrome. *Brain Dev.* 2001; 23:765–769. [PubMed: 11701291]
- Somer M. Diagnostic criteria and genetics of the PEHO syndrome. *J Med Genet.* 1993; 30:932–936. [PubMed: 8301648]
- D'Arrigo S, Grazia BM, Faravelli F, Riva D, Pantaleoni C. Progressive encephalopathy with edema, hypsarrhythmia, and optic nerve atrophy (PEHO)-like syndrome: what diagnostic characteristics are defining? *J Child Neurol.* 2005; 20:454–456. [PubMed: 15968934]
- Klein A, Schmitt B, Boltshauser E. Progressive encephalopathy with edema, hypsarrhythmia and optic atrophy (PEHO) syndrome in a Swiss child. *Eur J Paediatr Neurol.* 2004; 8:317–321. [PubMed: 15542387]
- Field MJ, Grattan-Smith P, Piper SM, et al. PEHO and PEHO-like syndromes: report of five Australian cases. *Am J Med Genet A.* 2003; 122A:6–12. [PubMed: 12949965]
- Bainbridge MN, Wang M, Wu Y, et al. Targeted enrichment beyond the consensus coding DNA sequence exome reveals exons with higher variant densities. *Genome Biol.* 2011; 12:R68. [PubMed: 21787409]
- Alfadhel M, Yong SL, Lillquist Y, Langlois S. Precocious puberty in two girls with PEHO syndrome: a clinical feature not previously described. *J Child Neurol.* 2011; 26:851–857. [PubMed: 21596701]
- Chong JX, Buckingham KJ, Jhangiani SN, et al. Centers for Mendelian Genomics. The genetic basis of Mendelian phenotypes: discoveries, challenges, and opportunities. *Am J Hum Genet.* 2015; 97:199–215. [PubMed: 26166479]
- Gambin T, Jhangiani SN, Below JE, et al. Secondary findings and carrier test frequencies in a large multiethnic sample. *Genome Med.* 2015; 7:54. [PubMed: 26195989]
- Nakamura K, Kodaera H, Akita T, et al. De Novo mutations in GNAO1, encoding a Galphao subunit of heterotrimeric G proteins, cause epileptic encephalopathy. *Am J Hum Genet.* 2013; 93:496–505. [PubMed: 23993195]
- Dattani MT, Martinez-Barbera JP, Thomas PQ, et al. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. *Nat Genet.* 1998; 19:125–133. [PubMed: 9620767]

13. Tajima T, Hattorri T, Nakajima T, et al. Sporadic heterozygous frameshift mutation of HESX1 causing pituitary and optic nerve hypoplasia and combined pituitary hormone deficiency in a Japanese patient. *J Clin Endocrinol Metab.* 2003; 88:45–50. [PubMed: 12519827]
14. Thomas PQ, Dattani MT, Brickman JM, et al. Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia. *Hum Mol Genet.* 2001; 10:39–45. [PubMed: 11136712]
15. Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. *N Engl J Med.* 2013; 369:1502–1511. [PubMed: 24088041]
16. Yang Y, Muzny DM, Xia F, et al. Molecular findings among patients referred for clinical whole-exome sequencing. *JAMA.* 2014; 312:1870–1879. [PubMed: 25326635]
17. Weaving LS, Christodoulou J, Williamson SL, et al. Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. *Am J Hum Genet.* 2004; 75:1079–1093. [PubMed: 15492925]
18. Montini E, Andolfi G, Caruso A, et al. Identification and characterization of a novel serine-threonine kinase gene from the Xp22 region. *Genomics.* 1998; 51:427–433. [PubMed: 9721213]
19. Masliah-Plachon J, Auvin S, Nectoux J, Fichou Y, Chelly J, Bienvenu T. Somatic mosaicism for a CDKL5 mutation as an epileptic encephalopathy in males. *Am J Med Genet A.* 2010; 152A:2110–2111. [PubMed: 20602487]

FIGURE 1.

Facial dysmorphic features, brain imaging studies and segregation analysis of disease-causing mutations in patient IMD1. The patient presented with typical progressive encephalopathy with edema, hypsarrhythmia and optic atrophy (PEHO)-associated dysmorphic features including microcephaly, facial edema, pear-shaped face, open mouth, downturned corners of the mouth. Brain imaging demonstrated cerebral and cerebellar atrophy. The patient was found with *de novo* mutations: ch16:56226501G>A (c.134G>A, p.Gly45Glu) in *GNAO1* and chr3:57233922G>A (c.25G>A, p.Ala9Thr) in *HESX1*. (The color version of this figure is available in the online edition.)

FIGURE 2.

Facial characteristic and brain magnetic resonance imaging demonstrating cerebral atrophy without cerebellar involvement in patient IMD3. Whole-exome sequencing (WES) analysis identified a *de novo* *CDKL5* mutation, chrX:18606145C>T (c.626C>T, p.Pro209Leu). (The color version of this figure is available in the online edition.)

TABLE

Clinical Characteristic of Patients With PEHO Syndrome (IMD1, IMD2) and PEHO-Like Syndrome (IMD3, IMD4)

Patient ID	IMD1	IMD2	IMD3	IMD4
Diagnosis	PEHO	PEHO	PEHO-like	PEHO-like
Mutated gene	<i>GNAO1</i> <i>HESX1</i>	–	<i>CDKL5</i>	–
Sex	F	F	M	F
Age at evaluation	6 yr	4.5 yr	6 yr	1 yr
Age of onset	Infancy	Infancy	Infancy	Infancy
Severe hypotonia	+	+	+	+
Seizures (age of onset)	+	+	+	+
	(4 days)	(8 days)	(6 wk)	(6 mo)
Profound psychomotor delay with lack of developmental progress	+	+	+	+
Abnormal/loss of visual fixation with optic atrophy by the age of 2 years	+	+	–	+
Cerebral atrophy	+	+	+	–
Cerebellar atrophy	+	+	–	–
Dysmorphic features including narrow forehead, epicanthal folds, short nose, open mouth, receding chin, tapering fingers	+	+	+	+
Edema of the face and limbs	+	+	+	+
Abnormal ABER	+	+	+	NA
Array CGH	normal	normal	normal	normal

Abbreviations:

ABER = auditory brainstem evoked response

PEHO = Progressive encephalopathy with edema, hypsarrhythmia and optic atrophy